MS Drug Development Agreement Based On WEHI’s Medicinal Chemistry July 3, 2008
Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany- based pharmaceutical company, Merck Serono. Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions.

add to del.icio.us
Print This Post































Leave a Reply